Cancer & epigenetic therapeutics
Disease-driving mechanisms, chromatin regulators and molecular recognition in cancer, with selective chemical modulation to generate chemical probes, validate targets and inform epigenetic drug discovery.
Structural & chemical biologist · Research leader · Drug-discovery scientist
Lukasz Jaremko, PhD
Understanding molecules. Building technologies for life and health.
Structural & chemical biology · Drug discovery · NMR & biophysics · Scientific assessment
I investigate how biomolecules work, change in disease and respond to chemical intervention. I combine structural biology, NMR, biophysics, chemical biology, metabolomics and computation to reveal mechanisms, assess tractability and guide drug-discovery, diagnostic-development and technology decisions.
Portrait
Molecular scheme
Profile
Molecular mechanisms, dynamics and discovery.
My research focuses on the fundamental molecular machinery of life—proteins and nucleic acids— how they function, interact with small molecules and change in disease. I work especially on difficult molecular systems where dynamics, transient interactions, hidden binding sites and heterogeneous states determine function and druggability.
I use structural, spectroscopic, biophysical, chemical and computational approaches to characterize molecular structure, dynamics and interactions, track and identify small molecules, and analyze complex molecular systems. The goal is practical: understand mechanism, discover and design ligands, evaluate what is experimentally supported and determine what should be tested next.
Methods
NMR spectroscopy · X-ray crystallography · cryo-electron microscopy (cryo-EM) · AI-supported structural modelling · biophysical chemistry · chemical biology
Scientific focus
Mechanisms, molecular recognition and tractable opportunities.
Difficult targets & cryptic binding sites
Structural dynamics and biophysics to reveal cryptic binding sites, assess tractability and identify new opportunities for chemical-probe and drug-candidate discovery.
Protein dynamics & aggregation
Flexible proteins, intrinsically disordered systems and oligomeric states—including tau and α-synuclein—with emphasis on mechanism and applications toward inhibitor and fluorescent-probe development in neurodegenerative disease.
Structural methods & molecular analysis
NMR spectroscopy, X-ray crystallography, cryo-EM, complementary biophysics and AI-supported structural modelling for molecular structure, dynamics and ligand binding, together with metabolomics and computational methods to detect, track and identify small molecules and their interactions in complex biological systems.
Integrated drug discovery
Target validation, assay strategy, screening, structural and biophysical evidence, ligand characterization and experimental de-risking—from mechanism to chemical probes and drug-candidate decisions.
Methods & technology development
Developing and integrating spectroscopic, analytical and computational methods that improve how molecular systems are measured, interpreted and applied in discovery, diagnostics and biotechnology.
Scientific assessment
I assess the science behind targets, technologies and discovery programs.
I focus on defining the mechanism, examining key assumptions, identifying scientific risk and determining which experiment or analysis would most reduce uncertainty.
I have also worked with companies on scientific analysis, feasibility, applicability and the practical limits of proposed technologies and research directions.
Therapeutic targets & mechanisms
Biological rationale, target tractability, mechanism, differentiation and the strength of the evidence supporting a therapeutic hypothesis.
Scientific & technical assessment
Review of data quality, reproducibility, claims, key assumptions and scientific risk, including technical due-diligence support and assessment of feasibility and applicability.
Drug-discovery programs
Experimental logic, assay strategy, structural and biophysical validation, ligand evidence and the next steps needed to de-risk a program.
Technologies & scientific platforms
Scientific value, feasibility, limitations, differentiation and practical utility of molecular, structural, biophysical, analytical and computational technologies.
Biotechnology & pharma
Life-science consulting
Scientific due-diligence support
Academic & translational institutes
Technology developers
Scientific leadership
Building research programs, teams and scientific capability.
Since 2017, I have led independent research programs and teams, recruited and mentored scientists, built collaborations and developed capabilities spanning structural biology, NMR, biophysics, proteomics, metabolomics and drug discovery.
I build and sustain collaborations across universities, research institutes, hospitals and industry, combining scientific depth with clear prioritization, rigorous evidence and practical execution.
>$7Mcompetitive funding supporting research programs since 2019
Since 2017independent research leadership
100+scientific publications
30+researchers and trainees mentored
Scientific record
Research output and professional profile.
Contact
Research leadership, discovery and scientific assessment.
Academic leadership, biotech and pharma, scientific assessment, due-diligence support, technology evaluation, drug discovery and interdisciplinary collaboration.
Direct contact
[email protected]Research / faculty opportunities · Scientific assessment · Technology evaluation